Eli Lilly is one of the country's oldest drug manufacturers, notable for introducing the world to Prozac. This year, it was one of the pharmaceutical companies caught up in Congress's investigation into the high price of insulin, but that didn't seem to have dampened the company's market performance.

Drugmaker Eli Lilly has reached a settlement with insulin buyers following six years of litigation. The company agreed to pay a $13.5 million settlement and continue its cap on users' out-of-pocket costs for four years.

Under the settlement, insulin users unable to qualify for the $35-a-month cap — people who no longer use Eli Lilly insulin or those now enrolled in the Medicare and Medicaid programs — may tap into the $13.5 million fund, which also is being used to pay administration costs and fees for the plaintiffs' attorneys.